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Despite intensive investigation, the essential mechanisms of allograft  rejection or 
tolerance have remained obscure. Although there is now no doubt that juvenile as 
well  as adult individuals  respond to foreign tissue grafts with production of serum 
antibodies  against  the alloantigens  (isoantigens)  of the donor,  the possible roles of 
such antibodies in graft rejection continue to be controversial. Circulating antibodies 
against  graft  antigens  are  generally  cytotoxic only for  dissociated  and  especially 
lymphoid cells.  Solid  tissue  transplants  such as  skin,  kidney,  or tumors are  rarely 
vulnerable to serum antibodies alone. Indeed, such grafts often show prolonged sur- 
vival or enhancement as a consequence of passive transfer of specific antiserum to the 
graft recipient.  Much evidence suggests  that  specifically immune  lymphocytes are 
the essential agents in the destruction of most types of aUografts (1). This conclusion 
follows in particular from the often repeated finding that lymphocytes from immunized 
animals will adoptively transfer immunity to normal animals,  whereas even hyper- 
immune serum from comparable donors fails to do so. Allograft rejection  then has 
many of the characteristics of cellular hypersensitivity of the delayed- or tuberculin- 
type. The details of how immune lymphocytes or their transformed descendants kill 
foreign target cells are still unknown. Perhaps a special class of cell-bound antibodies 
or even  induced  enzymes may be involved.  The recent  discovery of four or more 
major classes  of circulating immunoglobulins, each with distinctive physico-chemical 
and biological properties as well as intraciass differences  (2, 3), adds new dimensions 
to the possibility that certain typical antibodies may be associated with transplanta- 
tion immunity. Thus the failure of whole hyperimmune serum  to mediate allograft 
rejection passively could be  attributable  to opposing effects of different molecular 
species of antibodies. 
Recently we have found that only macroglobulin (i.e.  19S or IgM) alloantibodies 
are inducible in infant or juvenile mice, whereas older mice regularly produce 7S IgG 
aUoantibodies in addition  to macroglobulins  (4).  Yet m~x4mal  transplantation  im- 
munity of the adult  type is inducible in neonates before even  macrogiobulin  aUo- 
hemaggiutinins are readily detectable  under diverse  tactics of immunization. How- 
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ever, plaque assay studies currently in progress reveal allohemolysin production by 
neonatal mice during the earliest period that transplantation immunity is detectible. 
An  important  question  then  is  whether  these  early  appearing macroglobulins are 
temporally and functionally associated with allograft refection. 
After much effort, a  sensitive agar plaque technique has been developed that 
allows detection of alloantibodies against both strong and weak histocompati- 
bility antigens in mice  as  well as  Syrian hamsters.  There  appears  to  be  no 
limitation in the  "weakness"  of the histocompatibility antigens demonstrated 
to  evoke  serum  antibodies  detectable  by the plaque  assay  employed  in  the 
present study.  The  development of a  sensitive and reproducible quantitative 
plaque  technique  to  measure  alloantibody production has  been fraught  with 
technical pitfalls requiring extensive empirical testing. 
Materials and Methods 
Animals.--Mice  of the following inbred strains were  used: A/J,  C57BL/6, the congeuic 
lines C57BL/10 ScSn (H-2  b)  and B10.A  (H-2~), and the congenic  lines C3H/DiSn (H-1 ~) 
and C3H.K  (H-lb). The A/J  (H-2 *) and C57BL/6  (H-2  b) lines also differ  with respect to 
many non-H-2 histocompatibility loci. The immunogenetic properties of H-2 and non-H-2 
histocompatibility genes and antigens in various congenic lines of mice have recently been 
summarized elsewhere  (5).  (A/J 9  X  C57BL/6C)  F1 hybrids were  produced for tests of 
antibody responses to an X-linked antigen. Three inbred strains of Syrian hamsters, desig- 
nated LSH, MHA, and BRC, and showing intermediate to weak histocompatibility differ- 
ences,  have also been under study. 
Imraunization.--All  adult  animals were  immunized intravenously via  the  retroorbital 
sinus or occasionally through a tail vein. Approximately 6 X  108 ailogeneic erythrocytes plus 
1  X  106 buffy coat  leukocytes were  routinely administered to  each  lightly anesthetized 
recipient in a single inoculation of 0.1 or 0.2 ml. In pilot experiments, the intravenous route 
was found to be preferable to other routes for sensitization of spleen cells. Because plaque 
production by control spleen cells from normal, old adult animals was often high, young 
adults of 8 to 12 wk of age were regularly used for immunization. 
Agar Plaque Technique.--The technique employed is basically similar to that devised by 
Jeme et al. (6) for measuring the responses  of individual antibody-producing cells of mice to 
sheep red cells in vitro. Our method as evolved over some 2 yr of empirical testing of allo- 
antibody (isoantibody) responses will be described, because reproducible results require more 
careful attention to details than is the case with the sheep cell system. 
The bottom agar layer, which subsequently serves as a base for the agar overlay contain- 
ing the test cells, was prepared as follows:  1%  (w/v) Innagar No. 2 is prepared in Hanks' 
balanced salt solution and dissolved in an Arnold sterilizer or by boiling water for 30 to 45 
rain. It is then cooled to about 70°C and DEAE dextran (50 rag/100 ml) is added. Sodium 
bicarbonate (7.5%) is then added to adjust the pH to 7. This agar is filtered under sterile con- 
ditions while still hot through a furmel containing "tint-free" cotton wrapped in fine gauze to 
remove coarse debris. The agar is then poured into sterile,  glass Petri dishes (100 X  15 ram) 
with fiat bottoms, about 20 ml agar per dish. Excess moisture may be removed from the piates 
by drying at room temperature or in a 37°C incubator for 25 to 30 rain. The plates can then 
be stored in a refrigerator for later use up to 5 days at about 5°C. 
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pared as follows: a 0.7% solution of Ionagar No. 2 (Oxoid Division, Consolidated Laboratories, 
Chicago Heights, Illinois) or Agarose (Bausch  & Lomb Inc., Rochester, New York) is pre- 
pared in Hanks balanced salt solution without DEAE dextran and NaHCOv The hot agar 
must then be uitracentrifuged at 27,000 g (15,000 P.PM in the Sorvall RC-2B, Ivan Sorvall, 
Inc., Norwalk, Connecticut), for 50-ml tubes in the SS-34 rotor) for 5 rain to sediment the 
fine particulate debris invariably present. The bottom 1 cm of solidified  agar gel from each 
50-ml tube containing debris is cut off and discarded. The remainder of the agar is melted, 
cooled to about 70°C, and DEAE dextran (50 rag/100 ml) is added with mixing. Streptomycin 
sulfate (0.3 mg/ml) and penicillin G sodium (300 units/ml) is then added and the pH adjusted 
to 7.0-7.2 with 7.5% NaHCOa. The agar is then distributed in 2.5-ml volumes into 2 X  15 cm 
tubes fitted with "Bacti-Capall" tops at 47°C until ready for use.  Use of complete Eagle's 
medium (including amino acids and fetal calf serum) in lieu of Hanks' solution has not im- 
proved the final results. 
The separate tubes of target blood cells and spleen cells are slowly warmed to room tem- 
perature or above (~25°C). After mixing well, 0.1 ml red cell suspension  is pipetted into 2.5 
ml agar solution at 47°C, followed by 0.2 ml spleen cell suspension.  After further mixing by 
rotation to avoid bubbling, the test cells are immediately poured onto the center of a previously 
prepared Ionagar plate and quickly dispersed over the entire surface. This mixing procedure 
is repeated with pouring of successive tubes and  the plates are left undisturbed  until the 
overlays have completely solidified  (~I0 mill). The cell-agar overlay suspension at the time 
of pouring has a pH of 7.0 or 7.1. 
The test plates are placed in a humid 5% CO2 incubator (National Appliance Company, 
Portland, model 3221) at 370C for 30 to 35 rain, followed by an additional 30 rain in an air 
incubator at 37°C. Prolonged exposure to CO¢ may result in excessive lowering of the pH. 
About 4 ml of absorbed guinea pig complement at a dilution of 1: 8 in modified barbitol buffer 
(5,5-diethylbarbituric acid, 2.875 g; sodium 5,5-diethyibarbiturate,  1.875 g; calcium chloride, 
anhydrous,  0.083  g; magnesium  chloride,  anhydrous,  0.238  g; sodium  chloride,  42.500  g; 
distilled water to 1 liter to give 4x stock solution) is then added to each plate with reincuba- 
tion at 37°C for 30 rain. Excess complement may then be poured off and the plates are held 
for an additional 2~  to 3 hr at 25°C prior to final counting of the plaques. Because guinea 
pig complement generally contains naturally  occurring antibodies  for mouse  cells  (giving 
agglutination titers of 1:16 to 1:32) which may promote spurious plaques, preabsorption of 
complement at 0°C is desirable to remove these antibodies. One volume of washed, packed 
erythrocytes is sufficient to completely absorb  15 volumes of guinea pig complement or pre- 
ferably 30 volumes of complement at a  1:2 dilution in modified barbitol buffer in 15 to 20 
rain. It is important that this antibody absorption be performed at 0°-2°C to minimize comple- 
ment fixation. Concurrent control plates should include replicate immune spleen cell- and/or 
normal spleen cell-target red cell suspensions  to which are added absorbed guinea pig comple- 
ment inactivated by preheating at 56°C for 30 rain. Control plates to which no complement is 
added  sometimes yield considerable numbers  of plaques after 3  hr  of incubation, possibly 
due to spleen cell lysis in the absence of serum factors. 
We could list a long series of variations in the above technique that led to less satisfactory 
results. The most desirable innovations are prior ultracentrifugation of overlay agar to remove 
fine particulate debris, inclusion of streptomycin and penicillin, incubation of test cells in a 
C02  tissue-culture  environment, and  use of guinea pig complement from which naturally 
occurring mouse-specific  antibodies have been absorbed. 
Preparat~n of Test Cedis  for Plaq~ Assays.--Target red cells are harvested via the sub- 
clavian  artery  or  retroorbital  sinus  into  acid-citrate-dextrose  solution  or isotonic citrate- 
saline. The blood cells are washed three times in isotonic saline in the cold. The buffy coat is 
commonly retained, since test results indicate that buffy coat-rich target cells yield as many 888  ALLOANTIBODY  PRODUCTION  AND  HISTOINCOMI~ATIBILITY 
(or even slightly more) plaques as compared to buffy coat-poor red cell suspensions.  About 1.2 
volumes phosphate-buffered saline (pH 7.4) or Hanks' solution is added to each volume of 
packed, washed red cells to yield approximately 600 to 700 X  l0  s red cells per 0.1 ml. Each 
batch of red cells is counted in a Neubauer chamber and placed in an ice bath until ready for 
use. 
The spleen cells must be harvested with special care to assure high viability and minimal 
clumping. A whole spleen is placed in a sterile Petri dish containing cold citrate-saiine (2.0% 
Na3 citrate, 0.5% NaC1)  as an anticoagulant; adherent fat is removed and the spleen mem- 
brane is then cut lengthwise with fine scissors and the spleen is transferred to a Kontes Duall 
tissue grinder containing about 3 ml ice cold Hanks' balanced salt solution. Spleen cell ag- 
gregates are disrupted in stepwise aliquots using minimal pestle pressure and free spleen cells 
at each step are poured into a centrifuge tube in the cold. The combined spleen cell suspension 
is initially centrifuged in the cold in an International Clinical Centrifuge (zero  to maximum 
speed and immediately back to zero)  to deposit any heavy debris without appreciable loss of 
cells. The cell suspension  is then washed twice in cold Hanks' solution in the clinical centri- 
fuge at 400 g. A final volume of about 1.6 ml spleen cell suspension is passed through a stain- 
less steel wire mesh filter fitted inside a  2 ml syringe to remove any remaining debris or cell 
clumps. This procedure provides sufficient  cells for seven test plates (0.2 ml each containing 
5 to 20 X  106 cells per plate) plus 0.2 ml for total nucleated cell and viability counts. Spleen 
cells harvested in this manner routinely show 85 to 90% viability on the basis of trypan blue 
or eosin-Y exclusion (0.1% w/v solutions in saline). 
Technique Variations and Problems in Plaque Scoring.--Among  various agar preparations 
tested, Oxoid Ionagar No. 2 has provided the best results with the least expense.  Supposedly 
highly purified agars contain just as much physical debris (algal stems and fibers)  and have 
not improved the sensitivity or reproducibility of the tests. The addition of DEAE dextran 
to the agar improves sensitivity, presumably by neutralizing the anticomplementary properties 
of the agar. Inclusion of the bottom layer of agar allows for absorption of hemoglobin from 
plaque-lysed red cells and assures a level surface with even distribution of the top overlay; 
more plaques are also discernible in general than with a single layer technique. Since spleen 
cells killed by freezing and thawing, or heating at 56°C for 15 rain, produce very few or no 
plaques, plaque formation is attributable to active secretion of antibody by viable cells. 
It is probable that  COs incubation facilitates plaque formation through maintenance of 
physiological conditions, including a pH near neutrality. Our CO2 incubation time is just long 
enough for the phenol red indicator in the medium to turn orange or yellowish-orange; the 
color soon returns to red with continuing incubation in air at 37°C. Fresh mouse red cells are 
routinely used for plating, since cells stored in the refrigerator become increasingly prone to 
spontaneous lysis.  Blood lymphocytes from immunized mice also produce plaques under the 
same conditions suitable for spleen cells. 
The size  of plaques produced ranges from about  0.1  to 0.7  ram.  Higher plaque counts 
associated  with  substantial  antibody  production  generally yielded more plaques  of larger 
diameter, whereas small plaques were most frequent in conjunction with weak responses.  Very 
tiny plaques of 0.1 to 0.2 mm diameter may be visualized and counted with the unaided eye by 
appropriate  backlighting,  or  with  a  photographic  enlarger.  Plaque  counts  were  routinely 
checked independently by two observers and suspicious plaques were checked again under the 
microscope. Although questionable "spurious plaques" may pose a  problem at times, under 
present conditions with moderate experience, most such plaques are readily identifiable. Air 
bubbles or gaps in the overlay are easily discerned. In early testing, before the test components 
and especially the agar had been cleaned up, plaques associated with coarse debris and small 
clumps of spleen cells were fairly common. 
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negative bacilli and/or Gram-positive cocci found in the spleens or in commercial comple- 
ment. High plaque counts may then appear even after only 3 to 4 hr of incubation, but such 
spurious plaques are also at least as numerous in control tests in the presence of heat-in- 
activated complement. In more recent testing, we have routinely added  streptomycin and 
penicillin to the overlay agar and sterilized our complement by passage through a Swiuny or 
other bacterial filter. Penicillin G sodium (300 units/ml) plus streptomycin sulfate (0.3 mg/ml) 
is sufficient to prevent bacterial proliferation up to 24 hr without impairing the secretion of 
antibodies. Although Kanamycin sulfate (Kantrex, Bristol Labs., New York) is an even more 
effective antibiotic at a concentration of 0.2 to 0.4 mg/ml with respect to the Gram-negative 
organisms encountered, it clearly represses alloimmune plaque production. However, no such 
repression is evident with this antibiotic in the mouse spleen cell-sheep red cell system under 
the same conditions. 
Substantial increases in plaque counts commonly occur after prolonged incubation and the 
number of plaques increases with time (8 to 24 hr). Increases in plaque counts, often to the 
extent of two to eight times the 3 hr count, regularly occur after overnight incubation at 23 °- 
25°C and significant increases occur even in the refrigerator. However, test plates that show 
few or no plaques after 3 hr of incubation usually show few additional plaques after overnight 
incubation.  Increases in plaque counts after prolonged incubation also occur with immune 
spleen cells in the presence of absorbed,  heat-inactivated complement. The late appearing 
plaques obviously deserve further study. Apart from instances of contamination with hemo- 
lytic bacteria,  they may be very tentatively ascribed  to  (a)  continuing synthesis and  late 
release of antibodies by spleen cells,  (b)  cellular immunity or allogeneic inhibition that  is 
complement-independent,  (c) late lysis of red cells coated with suboptimal numbers of lytic 
antibodies, and (d) release of enzymes or lysins from disintegrating leukocytes. Mouse spleen 
cells tested against autologous red cells consistently reveal low levels of probable autoimmune 
plaque production. Such autolmmunity is often notably high in old animals. 
Skin Crrafling.--Skin  grafts were made and scored by methods previously described (4, 5). 
Median survival times with their 95~o confidence limits were determined nomographically by 
the method of Litchfield (7). 
RESULTS 
Numerous  inbred  and  congeneic  strains  of mice and Syrian hamsters were 
found to respond to intravenous inoculation of allogeneic blood cells with the ap- 
pearance of plaque-forming spleen cells over a period of 3 to 13 days after pri- 
mary immunization.  The magnitude  of the alloantibody  responses in diverse 
strain combinations of mice was found in general to correspond to the strength 
of the histocompatibility  disparity  as measured by the median  survival  times 
(MST)  of  skin  allografts.  These  results  are  summarized  in Text-fig.  1  and 
Table I. The strongest histoincompatibility,  as detected in the A/J--> C57BL/6 
combination reflecting H-2 plus non-H-2 differences, is revealed by a skin allo- 
graft MST of 8.2 4- 0.5 days and a peak average plaque production of 29.6 per 
10 X  106 viable  spleen cells. At the other extreme,  the C3H --> C3H.K con- 
genic  combination,  showing  quite  weak histoincompatibility  reflected  in  an 
average  allograft  survival  time  of  91  days,  gave  only  feeble  production  of 
plaque-forming  cells  (PFC)  with a peak response of 3.7 per  10  X  10  e viable 
spleen cells. Although there were slight differences in the range of days (3 to 13) 
during which significant plaque production was detectible,  peak plaque produc- 890  ALLOANTIBODY PRODUCTION  AND  HISTOINCOMPATIBILITY 
t/on occurred much earlier (5  to 6 days) with H-2  differences than with the 
"weaker" H-Y or H-1 differences (9 to 10 days). In other words, weaker histo- 
compatibility differences were associated with a somewhat longer latent period 
and slower recruitment of plaque-formlng cells. However, these differences are 
relatively slight in comparison with the profound differences in allograft sur- 
vival times observed. The early allohemolysin production revealed by plaque 
assay is  clearly not  temporally correlated with rejection times  of allografts 
Donor 
strain 
A/J 
B10.A 
C~TBL]10 
M 
C57BL/6o  ~ 
C3H.K 
C3H 
TABLE I 
Summary of Mouse Spleen Cell Plaque Production in Relation to Strong and 
Recipient 
strain 
C37BL/6 
C57BL/10 
BlO.A 
CJ7BL/6  Q 
C3H 
C3H.K 
Weak His~ncom 
Histocompati- 
bility locus 
difference 
between 
donors  and 
recipients 
H-2 plus 
Non-H-2 
H-2 
H-2 
H-Y 
H-I 
H-1 
Skin allograft 
median survival 
times in days 
with range of 
rejection times 
m  parentheses 
8.2  4- 0.5~ 
(7-10) 
10.3 4- 1.2§ 
(9.-14) 
10.8  4-  1.5§ 
(9-14) 
28.0  4- 2.51l 
(14-75) 
29¶ 
(15-43) 
91¶ 
(35-124) 
~at/b///S/es 
Average 
plaque count 
per 10 X  10  e 
spleen cells at 
peak primary 
response* 
26.6  (29.6) 
15.6  (17.4) 
9.6  (10.7) 
15.1  (16.8) 
14.8  (16.4) 
3.3  (3.7) 
Peak  Range of 
plaque  primary 
pro-  plaque 
duction  production 
day 
6 
5 
5 
9 
10 
9 
days 
4-12 
3-12 
3-12 
4-13 
5-13 
8--12 
Average 
plaque 
count per 
10 X  106 
S~roleen cells 
In non* 
immunized 
control mice* 
3.6  (4.0) 
1.2  (1.3) 
1.1  (1.2) 
1.0  (1.1) 
1.5  (1.7) 
1.6  (1.8) 
*No. of plaques recalculated (X 1.11) in parentheses on the basis of 90% spleen cell viability as found by trypan 
blue or eosin-Y  exclusion  at time of testing. 
Cf. reference 4. 
§ Nine adult females of each strain were reciprocally  grafted with full-thlckness  skin. 
|  Cf. reference 8. 
¶ Cf. reference 9. 
across non-H-2 barriers. The detailed results of these experiments are given in 
Table II. It should be noted that each recipient was immunized with sufficient 
leukocytes (1.0  to 1.2  X  106) in addition to 6 to 8  X  l0  s red cells to induce 
substantial or maximal skin transplantation immunity at the time allohemol- 
ysins were being produced (5, 10). In the combinations A/J--~ BL/6,  BL/10--~ 
B10.A, and B10.A --~ BL/IO,  increasing the single immunizing dose two- to 
eighffold did not increase the plaque counts at 5, 6, or 8 days. 
Tmmunization via orthotopic skin allograft rejection alone has led to the ap- 
pearance of substantial numbers of PFC. Spleens from four B10.A females gave 
1.5, 14.8, 24.2, and 26.6 plaques per 10 X  10  ° spleen cells on BL/10 target red 
cells at 2 to 3 days after complete rejection of first-set BL/10 skin allografts. W, H. II~LDEM.ANN AND W. PINI~E~gTON  891 
Under  the  same  conditions  in  the  reciprocal combination  with  four  BL/10 
female recipients, average plaque counts of 0.3, 0.7, 0.8, and 6.6 per 10  X  l0  s 
spleen cells were obtained. We have no explanation other than the late time of 
testing for the wide variation in numbers of PFC detected under these condi- 
3O 
25 
20 
15 
I0 
5 
0 
_1 
.J 
W 
O 
Z 
W  25 
hi 
~  20  Q. 
0 
5 
U.I 
w 
~  25 
_1  20 
15 
0 
A/J,-.~BL/6  ___~__, 
5  I0  15 
BL/IO-'),.-B/O,A 
....  ~--3 
5  I0  15 
b 
BIO,  A-""~BL//O 
0  5  I0  15 
d 
8L/eJ-..~eL/6~. 
0  5  I0  15 
e  f 
C3H.  K.-.~-C3H  C3H,.-~.-C3H.I( 
,go 
.....  T  i  ---  ,~  ,  .'i  ~,. ~,  ..  ~  ~3"L">J  ~.~ 
0  5  I0  15  0  5  I0  15 
DAYS  AFTER  IMMUNIZATION 
Text-Fig. 1. Appearance of plaque-forming  spleen cells in different allogeneic  and congenic 
mouse strain combinations following a single intravenous injection of blood cells. Each point 
represents the mean response of 4 to 7 mice. Dashed horizontal lines indicate average level of 
control plaques produced by normal spleen cells. 
tions. It remains to be determined whether the time-course of appearance and 
recruitment of PFC induced by skin allograft rejection are commensurate to 
the reactions following a  single intravenous injection of allogeneic cells. 
The quantitative courses of the immune reactions in the four "stronger" re- 
sponses as shown in Text-figs. 1 and 2 are in accord with the assumption of an 
exponential increase in plaque-forming cells for 2  to 4  days until peak levels 
were reached.  The time for doubling the number of PFC may be as short as °~ 
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7 to 8 hr during the phase of exponential increase in the most responsive A/J--+ 
BL/6 and B10.A --* BL/10 combinations. However, this multiplication could 
well include commitment of preexisting virgin cells as well as proliferation of 
antibody-producing  cells.  The  subsequent  rapid  decrease  in  plaque-forming 
cells was followed 2 to 4 days after the peak response by a moderate, renewed 
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Text-Fig.  2. Semilogarithmic  representation of  time-course of  appearance of  plaque- 
forming spleen cells in four allogeneic strain combinations of mice after a single imm,miv-~tion. 
Note exponential increases in numbers of plaque-forming cells until peak responses were 
reached. 
rise in activity before plaque production diminished to low control levels. This 
secondary rise suggests  interruption of continuing induction of 19S antibody 
synthesis,  perhaps  as  a  consequence  of feedback  inhibition with onset  of 7S 
antibody production which is suboptimally revealed by guinea pig complement 
(11).  The increases  in plaque-formlng  cells in  the  congenic  C3H ~  C3H.K 
combinations  do not appear  to be  logarithmic in  character.  However,  much 
larger numbers  of these mice will have  to be  tested,  especially at additional 
donor cell dosage levels, before this question is resolved. 
Sufficient tests have been done with other allogeneic combinations of mice 894  ALLOANYIBODY  PRODUCTION  AND  HISTOINCOMPATIBILITY 
and Syrian hamsters to demonstrate that our plaque assay technique is suitable 
for measurement of allohemolysin responses in general. High levels of PFC were 
found in A/J females at 5 to 7 days after immunization with H-2 incompatible 
C57BL/6 female blood ceils. The H-Y antigen as expressed in the A/J male --* 
A/J female combination has in a limited number of tests led to the appearance 
of fewer PFC than found in the C57BL/6 male ~  C57BL/6 female combina- 
tion. A moderately strong X-linked histocompatibility antigen was found to 
distinguish the  A/J and  C57BL/6 strains  such  that  single  C57BL/6 male 
skin grafts were rejected by 9  (A/J9  X  BL/6c~)F1 adult males with a me- 
dian survival time of 28.0 days with 95%  confidence limits of 23.8 to 33.1 
days.  A  single  intravenous  immunlzation  of  (A/J9  X  BL/6c~)F1  males 
with 6 ×  108 F1 sibling female red cells, involving the same X-linked antigen, 
gave a  peak plaque  production of about  15  per  10 X  106  spleen  cells at  10 
days. From these results, it may be concluded that the various non-H-2 histo- 
compatibility antigens thus  far  investigated are  also  blood  group  antigens 
capable  of eliciting  the production of hemolysins.  Although we presume  on 
the basis of earlier work that these antigens  are more abundantly present in 
leukocytes  than  erythrocytes,  quantitative  evaluation  of  this  question  in 
terms of relative immunogenicities  for stimulation of PFC has not been  at- 
tempted.  However,  leukocyte-enrlched  and  leukocyte-depleted  preparations 
of target red ceils appear in general to be about equally susceptible to plaque 
production. 
Preliminary results  of plaque formation by spleen cells following a  single 
primary immunization with 0.5  to 1.0 X  109 red cells plus  buffy coat leuko- 
cytes have been obtained with the following strain combinations  of hamsters: 
BRC ~  MHA,  LSH ~--- MHA,  and  BRC ~  LSH.  Peak  responses  ranging 
from 14 to 24 PFC per 10 X  106 spleen cells were detected in all combinations 
at about 9 to 11 days after immunization. This consistent,  early alloantibody 
response  was surprising  on two counts: (a)  the immunity manifested toward 
first-set  skin allografts  ranges from very weak in LSH ~  MHA (12) to inter- 
mediate in the BRC interstrain combinations  with MST's of about 4 wk (13); 
(b)  even after hyperlmmunization, many previous  attempts to detect serum 
alloantibodies  by diverse serological techniques  have given only irregular  low 
titers or negative results. 
After rest periods  of 2  to 4  wk,  booster  immunizations of hamsters have 
yielded heightened and earlier secondary responses reflected in two- to four- 
fold increases  in PFC over the maximal plaque  counts observed  in primary 
responses.  Antiserums  taken from hyperimmunized hamsters at times when 
PFC activity was high have exhibited sufficient titers of hemolysins in stand- 
ard  tests  with  guinea  pig  complement  to  facilitate absorption  analyses of 
strain-specific  differences.  Such  analyses  are  now  in  progress. Severalfold 
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liminary  tests  of mice  given  booster inoculations  of allogeneic  blood cells. 
In these situations, optimal schedules  and tactics of immunization remain to 
be determined and may weU depend on the "strength"  of the antigenic dis- 
parity involved. 
Five adult A/J female mice immunized with 5 X  108 sheep red cells by the 
intravenous route and tested for PFC after 4 days by the same method applied 
in  the  a11ogeneic combinations  have  given  an  average  of  1310  plaques  per 
10 X  106 spleen cells with mouse ceU-absorbed complement.  Slightly but not 
significantly  higher  plaque  counts  were  obtained  in  concurrent  tests  with 
unabsorbed  complement,  indicating  that  the  naturally  occurring  mouse- 
specific antibodies in guinea pig serum do not block the release  of antibodies 
by mouse spleen cells. Otherwise identical tests employing unabsorbed or ab- 
sorbed,  heat-inactivated  complement  gave no  plaques  or very few plaques. 
The various types of hemolytic plaques produced by immune spleen cells 
in the major test systems studied are illustrated comparatively in Figs.  1 to 6. 
In  general,  allolmmune  plaques  are  smaller  and  develop less  rapidly  than 
those produced against sheep erythrocytes by either mouse or hamster spleen 
cells. 
DISCUSSION 
Although the agar plaque technique as employed in the present studies is 
essentially simple, close attention to technical details has proved important  in 
the  attainment  of  reproducible  results.  Moreover,  prior  ultracentrifugafion 
of overlay agar  to remove particulate  debris,  addition  of streptomycin and 
penicillin  to inhibit  spleen-derived bacteria,  incubation of test cells in a  5 % 
CO2  environment,  and  use  of  guinea  pig  complement  from  which  natural 
mouse-specific  antibodies have been absorbed appear  to be important.  Such 
refinements  appear to be less critical in the sheep red cell-mouse  spleen cell 
system where  ten-  to  fiftyfold higher  plaque  counts  are  readily obtainable 
(14,  15)  under  comparable  conditions.  This  heightened  responsiveness  to 
sheep  cells  in  comparison  with  allogeneic  cells  is  not  surprising  in  view of 
the  relative  antigenic  disparities  involved.  Reasonably reproducible  plaque 
counts in our hands have required testing whole spleens rather than portions 
thereof,  a  finding  consistent  with  the  evidence of Nakano  and  Braun  (16) 
that  PFC occur in spleens  in a  nonrandom  distribution.  In this  connection, 
we are  still  concerned  about relative  plating  efficiency;  i.e.,  the  number  of 
plaques obtained as a  function of the number of potential PFC present in a 
given spleen.  Spleen  cell  suspensions  from immunized  an;reals  often appear 
to be more  "sticky" than  those from normal  animals.  Cells  which tend  to 
remain in clumps are finally removed by filtration and are therefore not tested; 
on the other hand,  excessive  manipulation  to disperse all clumped cells has 
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Calculations  of  numbers  of  PFC  by  other  investigators  have  not  taken 
spleen  cell  viability determinations into account.  For comparative purposes, 
PFC counts given in the present paper unless otherwise noted are also calcu- 
lated on the basis of 100% viability. However, with our actual viability counts 
regularly around 90 %, it should be noted that the numbers of PFC per 10  X  106 
v/ab/e spleen cells are increased by a factor of 1.11 (see Table I). The control 
level of 1 to 2 PFC per 10 X  106 spleen cells found in young adults of most 
mouse and hamster strains  is  4  to 5  times less  than the number of control 
plaques found with respect to sheep red cells  (14,  15, 17). In our intraspecific 
experiments,  the  same  low levels  of PFC  are  found regardless  whether  the 
normal spleen cells  are  tested against autologous or allogeneic red cells.  We 
presume  that  these  PFC  are  largely autoimmune since  they often increase 
substantially with advanced age  (18).  In  the  sheep  cell-mouse system, the 
higher levels of normal PFC may be attributable partly to naturally occurring 
immunization with heterophile antigens having determinants similar to some 
found on sheep cells and partly to spurious plaques. Alternatively, Jerne (15) 
favors the idea that these PFC differentiate spontaneously and may be present 
in  the  absence  of an antigenic stimulus. 
Since nucleated cell counts of whole spleens even from animals of the same 
strain and age may vary from about 80 to 150 million cells, it is important to 
express plaque counts per 106 spleen cells or multiples thereof rather than per 
spleen. The number of plaques obtained under the conditions described was 
not significantly affected by the sex of the donors or recipients in the BL/10 --> 
B10.A and C3H--> C3H.K combinations. In other combinations not involv- 
ing  sex-associated  antigens  only female  donors  and  recipients  were  tested. 
Although we have not systematically investigated the dosage of donor cells 
as an experimental variable in all strain combinations studied, over the range 
of 1 X  108 to 4 X  108 red cells, closely similar responses  have been  obtained. 
This dosage range which includes 160,000 to 6.4 million buffy coat leukocytes 
may be suboptimal in the weaker histoincompatible combinations on a  single 
injection basis,  even though similar dosages yield maximal responses toward 
sheep  cells  (15).  It  is  entirely possible  that  the  dosage  of allogeneic donor 
leukocytes is more decisive than the red cell dosage, since the former are known 
to be a  much richer source of most alloantigens (cf. references 1,  11). 
The results reveal an overall lack of correspondence between the times or 
rates of skin allograft rejection and the time of appearance of plaque-forming 
cells.  In other words, prolonged allograft survival was not correlated with a 
commensurate delay in the initial occurrence of plaque-formlng cells.  Never- 
theless,  peak  plaque  production  occurred  earlier  and  reached  higher levels 
across  the  stronger  histocompatibility barriers  in  general  accord  with  the 
rapidity of allograft rejection. Weak transplantation barriers  were not asso- 
ciated  with  proportionate  delays  in  the  induction  of  antibodies,  but  were 
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Much  evidence strongly suggests  that  transplantation  immunity  and  hu- 
moral alloantibody production are elicited by antigens with the same or similar 
determinant  groups  (1).  The  present  evidence supports various earlier  indi- 
cations  that  these  two manifestations  of allolmmune  responsiveness  depend 
upon distinctive  immunological  processes  (4,  19).  The  times of inception  of 
transplantation  immunity  and  hemolysin production  were disparate  in  con- 
junction with weak histocompatibility differences. The question arises whether 
additional  subpopulations  of antibodies are being produced, but remain un- 
detected by the present plaque assay.  It is generally assumed that  only 19S 
antibodies are produced in significant  amounts in an  early primary response. 
However, adult C57BL/6 or A/J mice may produce readily detectable titers 
of both 19S and 7S alloantibodies as revealed by analytical ultracentrifugation 
(4) within 9 days after reciprocal  primary immunization. The extensive studies 
of Winn (11) indicate that guinea pig complement is efficiently activated only 
by 19S mouse antibodies,  whereas rabbit  complement works efficiently  with 
7S mouse antibodies.  Thus it is possible that  numerous PFC elaborating  7S 
hemolysins, especially late in the primary response,  were missed in the present 
analysis.  Replicate assays employing both guinea pig and rabbit complements 
should clarify this point. In a strict sense then, the relationships discerned in 
the present study may be relevant only to  19S  hemolysins.  Other molecular 
spedes of antibodies may also be produced relatively early  and require other 
means of detection. 
The results show that H-l, H-Y, and H-X antigens in the mouse and other 
weak H  antigens in Syrian hamsters are also erythrocyte antigens. For as yet 
unknown  reasons,  detection  of  these  weak  histocompatibility  antigens  by 
standard serological techniques has not been achieved on a reproducible basis 
in the past. Further testing in relation to known times of peak plaque produc- 
tion should prove fruitful, especially following booster injections. 
SIYMMARY 
A plaque technique which provides a sensitive and quantitative determina- 
tion  of allohemolysin  (isohemolysin)  production  by lymphoid  cells  of mice 
and Syrian hamsters is described. Much ongoing  attention has been given to 
minimizing  sources of spurious  plaques  while  improving  the  reproducibility 
of  the  technique.  Primary  intravenous  immunization  with  allogeneic  blood 
cells led to the early appearance of plaque-forming spleen cells responding to 
both strong and  weak histocompatibility antigens  in inbred  strains  of mice. 
The  strongest  histoincompatibility  (A/J--* BL/6),  characterized  by  H-2 
plus non-H-2 differences  and a  median Skin allograft survival time of 8,2 4- 
0.S days, gave a peak average plaque production of 29.6 per 10  X  10  e viable 
splee  n  cells after 6 days. At the other extreme with an average allograft sur- 
vival time of 91 days, C3H(H-1  ") ---> C3H.K(H-1  b) showed a feeble production 
of plaque-forming cells with a peak response of 3.7 per 10 X  106 viable spleen 898  ALLOANTIBODY  PRODUCTION  AND  HISTOINCOMPATIBILITY 
cells  at 9 days. Histocompatibility antigens determined by genes at the H-l, 
H-Y,  and  H-X  loci  were  demonstrated to  be  erythrocyte antigens as  well. 
Peak plaque production occurred earlier and reached higher levels across the 
stronger histocompatibility barriers  (H-2 plus non-H-2 or H-2 alone) in tem- 
poral accord with the rapidity of skin allograft rejection. Weak H-Y or H-1 
differences leading to prolonged aJlograft survival were associated with moder- 
ate,  but not commensurate delays in  the initial occurrence and recruitment 
of plaque-forming cells. With one exception (C57BL/10 --* B10.A), the average 
plaque  counts  found  at  the  peak  of  the  primary responses  were  inversely 
proportional to the median survival times of skin allografts in the same strain 
combinations.  Nevertheless,  in  light  of  the  disparity between  the  times  of 
allograft rejection and the time course  of appearance  of plaque-forming cells 
with  the  "weaker"  congenic combinations,  the  early 19S  antibodies  do not 
appear to be directly involved in allograft rejection. 
There  appears  to  be  no  limitation in  the  weakness  of histocompatibility 
antigens capable of evoking antibodies detectible by plaque assay. The extent 
to which molecular species of mouse antibodies other than 19S hemolysins are 
induced and detected under the conditions employed remains to be determined. 
The  responses  in  strain  combinations involving stronger  histocompatibility 
barriers  were characterized by exponential increases in plaque-forming cells, 
for 2 to 4 days until maximal levels  were reached. Repeated immunization in 
several trials led to substantial increases over the maximum primary response 
in  the  number  of  demonstrable  plaque-forming  cells.  Further  preliminary 
results are reported concerning alloimmune plaque production in three strains 
of  Syrian hamsters  exhibiting intermediate to  weak  histocompatibility  dif- 
ferences. 
The authors acknowledge  the expert technical  assistance of Mrs. Beth Teviotdale. 
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EXPLANATION OF PLATES 
PLATE 88 
FIG. 1.  Typical individual  plaque produced by immune A/J mouse spleen  ceils 
against sheep erythrocytes in presence of absorbed guinea pig complement.  Notable 
variation in size and clarity of individual  plaques is the rule.  Approximately X  100. 
Fro. 2. Larger alloimmune plaque produced by C57BL/6 mouse spleen cells against 
A/J erythrocytes in presence  of absorbed  guinea  pig complement at  6  days after 
immunization.  These larger plaques,  though uncommon,  are  often associated  with 
small dumps of spleen ceils. Approximately X 100. TI-IE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL.  124  PLATE  88 
(Hildemann and Pinkerton: Alloantibody production and histoincompatibility) PLATE 89 
FIG. 3. Typical small alloimmune plaque produced by C57BL/6 mouse spleen cells 
against  A/J erythrocytes in presence of absorbed guinea pig  complement  at 6 days 
after immunization.  Note single spleen cell in center of plaque.  Compare  with  Figs. 
1 and 2 at same magnification.  Approximately  X  100. 
F~c. 4. An individual alloimmune plaque  produced  by MHA hamster  spleen cells 
against  BRC erythrocytes in presence of absorbed guinea pig complement at 13 days 
after  immunization.  Approximately  X  100. THE  JOURNAL OF  EXPERIMENTAL  MEDICINE VOL. 124  PLATE  89 
(Hildemann and Pinkerton: Alloantibody production and histoincompatibility) PLATE 90 
FIGS. 5 and 6. Individual alloimmune plaques produced by MHA hamster spleen 
cells  against  BRC erythrocytes in presence of absorbed guinea pig complement at 
13 days after immunization. Note substantial variation in margins and diffuseness  of 
plaques in Figs. 4, 5, and 6 under magnification. Approximately  ×  100. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL. 124  PLATE QO 
(Hildemann and Pinkerton: Alloantibody production and histoincompatibility) 